# A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants

> **NCT01062477** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1056 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Haemophilus Influenzae Type B

## Interventions

- **BIOLOGICAL:** DTaP//PRP-T Combined Vaccine
- **BIOLOGICAL:** DTaP//PRP-T Combined Vaccine
- **BIOLOGICAL:** DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine

## Key facts

- **NCT ID:** NCT01062477
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-12
- **Target enrollment:** 1056 (ACTUAL)
- **Last updated:** 2011-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062477, "A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01062477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*